Contributors
-
TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Category Archives: Business
Threats to Mankind from Drug Resistant Bacteria and Viruses
The risk of an end to the human race may sound like science fiction. However, there are only a small number of threats that could theoretically lead to the extinction of mankind. The four main concerns that most experts share … Continue reading
Posted in Business, David Cameron, Drugs, Global Health, GPs, International, Most Significant, NHS, Pharma, Public Health, Rare conditions, Research, Vaccination
Tagged 2020health, AIDS, amoxicillin, Antibacterial, antibiotics, antiviral, Augmentin, bacteria, bacterial susceptibility, beta-lactam, beta-lactamase, bureaucracy, carpenem, cephalosporin, Ebola, end of mankind, Gilead, hepatitis, Hospitals, Human, hygiene, isolation, monobactam, NICE, pathogen, penicillin, plague, PPRS, prescribing, prevention, Prime Minister, Pseudomonas, R & D, R&D, rabies, Research, Research and development, resistance, sofosbuvir, Sovaldi, vaccine, virus, WHO
Comments Off on Threats to Mankind from Drug Resistant Bacteria and Viruses
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Posted in Business, Drugs, Innovation
Tagged acetylcholine, acetylcholinesterase, Alzheimer's, block-buster, British Biotech, C1-inh, cholinesterase, David Jack, glutamate, hub, innovation, marimastat, medicine, mental health, Neurochem, NICE, NMDA, pharmaceutical, R&D, Research, Sir David Jack
Leave a comment
Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing
Tagged 2020health, Andrew Lansley, Bowel Cancer UK, Cancer Research UK, Drugs, government, innovation, medicine, Multiple Sclerosis Society, pharmaceutical, R&D, value-based, value-based pricing
1 Comment
Guest Blogspot: Prevention is better than cure.
The economic consequences of preventing illness are highly complex. Just comparing the costs of prevention with the direct treatment costs that should be avoided is far too simplistic. The true economic impact of preventative measures can often only be assessed … Continue reading
Posted in Alcohol, Business, Children, Elderly, Health Bill, Healthcare, Information, Jeremy Hunt, NHS, Obesity, Patient choice, Patients, Policy, Uncategorized
Tagged accidents, alcohol, Andrew Lansley, arthritis, cancer, cardiovasculsr, cause of dsath, choice, elderly, government, health, Health Bill, injury, Jeremy Hunt, longevity, mortality, National Health Service, NHS, Obesity, Patients, prevention, Public Health, respiratory, smoking, tobacco
Leave a comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: Do private patients in the UK help or harm the NHS?
Private medicine like private education and first-class travel can stir up feelings of resentment between the “haves” and “have-nots”. A short blog like this one has no possibility of uniting stereotypical politicians from the left and right wings of politics. … Continue reading
Posted in Business, Department of Health, Drugs, Elderly, GPs, Health Bill, Health Team, Healthcare, Hospitals, Inequality, mental health, NHS, Nursing, Patient choice, Patients, Pharma, Policy, Private, Research
Tagged 2020health, choice, Consultant, Cosmetic Surgery, Dental, Department of Health, Drugs, elderly, Gamma Knife, General practitioner, government, GP, GPs, health, Health Bill, Medical Insurance, medicine, mental health, National Health Service, NHS, outcomes, patient, Patients, pharmaceutical, Prescription Charge, Private Hospital, Private Medicine, Private Patient, Research
Leave a comment
Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?
Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading
Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research
Tagged 2020health, Abbott, alcohol, AstraZeneca, bribes, criminal, dishonest, Drugs, General practitioner, government, GP, GPs, GSK, innovation, Kuno Sommer, law breaking, life expectancy, Lilly, medicine, misleading, National Health Service, NHS, Obesity, patient, Patients, Paxil, Pfizer, pharmaceutical, practolol, pricing, R&D, Research, Responsibility in healthcare, Seroquel, thalidomide, tobacco, Wellbutrin, wrongdoing, Zhen Xiaoyu
Leave a comment
2020health's Blog 
You must be logged in to post a comment.